Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 78, Issue 17-18, Pages 6337-6349Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-021-03910-x
Keywords
mRNA translation; eIF4A; Silvestrol; Rocaglamide; MYC
Categories
Funding
- Cancer Research UK [C2750/A23669]
- Bloodwise [14040, 14045, 16004, 16003, 13036, 18009]
- Southampton Experimental Cancer Medicine and Cancer Research Centers [C24563/A15581, C34999/A18087]
- Kay Kendall Leukaemia Fund [KKL0168]
Ask authors/readers for more resources
Signaling through the B-cell receptor (BCR) plays a crucial role in chronic lymphocytic leukemia (CLL), with eIF4A being identified as a key regulator downstream of BCR activation. Inhibitors of eIF4A have shown promising effects in reducing global mRNA translation, as well as inhibiting the expression of oncogenes such as MYC and MCL1. This suggests that targeting eIF4A may be a potential therapeutic strategy for CLL and other B-cell malignancies, particularly those dependent on MYC and/or MCL1 for proliferation and survival.
Signaling via the B-cell receptor (BCR) is a key driver and therapeutic target in chronic lymphocytic leukemia (CLL). BCR stimulation of CLL cells induces expression of eIF4A, an initiation factor important for translation of multiple oncoproteins, and reduces expression of PDCD4, a natural inhibitor of eIF4A, suggesting that eIF4A may be a critical nexus controlling protein expression downstream of the BCR in these cells. We, therefore, investigated the effect of eIF4A inhibitors (eIF4Ai) on BCR-induced responses. We demonstrated that eIF4Ai (silvestrol and rocaglamide A) reduced anti-IgM-induced global mRNA translation in CLL cells and also inhibited accumulation of MYC and MCL1, key drivers of proliferation and survival, respectively, without effects on upstream signaling responses (ERK1/2 and AKT phosphorylation). Analysis of normal naive and non-switched memory B cells, likely counterparts of the two main subsets of CLL, demonstrated that basal RNA translation was higher in memory B cells, but was similarly increased and susceptible to eIF4Ai-mediated inhibition in both. We probed the fate of MYC mRNA in eIF4Ai-treated CLL cells and found that eIF4Ai caused a profound accumulation of MYC mRNA in anti-IgM treated cells. This was mediated by MYC mRNA stabilization and was not observed for MCL1 mRNA. Following drug wash-out, MYC mRNA levels declined but without substantial MYC protein accumulation, indicating that stabilized MYC mRNA remained blocked from translation. In conclusion, BCR-induced regulation of eIF4A may be a critical signal-dependent nexus for therapeutic attack in CLL and other B-cell malignancies, especially those dependent on MYC and/or MCL1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available